Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606602 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
A Phase 1 study of Dyslipidemias and Hyperlipidemias, sponsored by Silence Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 8
- Study locations
NCT04606602 is a Phase 1 study of Dyslipidemias and Hyperlipidemias that has completed, run by Silence Therapeutics. The registered enrollment target is 70 participants, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT04606602, a Phase 1 study of Dyslipidemias and Hyperlipidemias, has completed, sponsored by Silence Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SLN360
Study Locations (8)
Other
- Monash Medical Centre - Clayton
- Amsterdam Medical Centre - Amsterdam
- Hammersmith Medicines Research - London
Florida
- Jacksonville Center for Clinical Research Ltd. - Jacksonville
- Progressive Medical Research - Port Orange
Ohio
- Metabolic and Atherosclerosis Research Center - Cincinnati
- Cleveland Clinic - Cleveland
Western Australia
- Linear Clinical Research - Perth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2023-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04606602
The ClinicalTrials.gov registry entry for NCT04606602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower). The listed sponsor is Silence Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dyslipidemias appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04606602 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04606602 about?
NCT04606602 is a clinical study titled "Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)". This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
What is the current status of trial NCT04606602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2020-11-18. Estimated completion is 2023-08-23.
What conditions does trial NCT04606602 study?
This clinical trial studies the following conditions: Dyslipidemias, Hyperlipidemias, Elevated Lp(a).
What interventions are being tested in trial NCT04606602?
The interventions under investigation include: Placebo (DRUG), SLN360 (DRUG).
Who is sponsoring clinical trial NCT04606602?
This trial is sponsored by Silence Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606602 being conducted?
This trial has 8 study locations across Florida, Ohio, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
COMPLETED · Phase 1
-
A Study of LY3475766 in Healthy Participants
COMPLETED · Phase 1
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
'Ai Pono Cooking Demonstrations
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.